ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

August 24, 2020 Articles 9:00 am

Today, ATAI Life Sciences, a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of  3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit